Skip to main content

Kooij Louise Frederika's Form 4 filing

NewAmsterdam Pharma Co N.V. (NAMS) · filed Sep 10, 2025

Accession no.
0000950170-25-114033
Filed
Sep 10, 2025
Trade date
Sep 9, 2025
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.87M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Kooij Louise FrederikaCIK 0002004379Officer (Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 9, 2025Ordinary SharesMOption exerciseAcquired+150,000$10.00+$1,500,000165,000Direct
Sep 9, 2025Ordinary SharesSSaleDisposed−53,104$25.31−$1,344,062.24111,896Direct
Sep 9, 2025Ordinary SharesSSaleDisposed−96,896$26.11−$2,529,954.5615,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 9, 2025Ordinary SharesMOption exerciseDisposed−150,000$0.00$0280,015Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)